Physicians' Academy for Cardiovascular Education

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##SCROLLER_ITEMS_FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##SCROLLER_ITEMS_FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Are new hypertension guidelines helpful for patients at high risk?

3' education - May 23, 2014 - CDMC Almaty - Dr Peter Meredith, Glasgow
##SCROLLER_ITEMS_FULL_TITLE##

Improving BP measurement for better hypertension management

3' education - Apr. 25, 2014 - CDMC Almaty - Prof Luis Ruilope, Madrid, Spain
##SCROLLER_ITEMS_FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield
##SCROLLER_ITEMS_FULL_TITLE##

Update on therapy-resistant hypertension: Novel pharmacotherapy or renal denervation?

10' education - Sep. 14, 2013

ESC Debate | Should hypertension be redefined?

ESC 2018 - debates

ESC 2018 In this debate, the different viewpoints supporting the European and American Guidelines on Hypertension were fiercely defended, although overlap prevails.

2018 ESC/ESH Guidelines for management of arterial hypertension

News - Aug. 27, 2018
Key messages of the 2018 ESC/ESH Guidelines for hypertension include no change in the definition of hypertension, treatment for those with high-normal BP and grade I hypertension and initiation of two-drug combination.

ESC 2018 Key messages of the 2018 ESC/ESH Guidelines for hypertension include no change in the definition of hypertension, treatment for those with high-normal BP and grade I hypertension and initiation of two-drug combination.

Summary | Diabetes: How to reduce risk from a cardiovascular perspective?

May 3, 2018 – Prof. Diederick Grobbee, MD

This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.

Even normotensive young blacks have a higher risk of hypertension than whites

Literature - July 19, 2018 - Thomas SJ, et al. - J Am Heart Assoc. 2018
Black individuals have a significantly higher risk for hypertension compared with whites, from young adulthood through middle age, irrespective of blood pressure before the age of 30 years.

Black individuals have a significantly higher risk for hypertension compared with whites, from young adulthood through middle age, irrespective of BP before the age of 30 years.

BP response to exercise is exaggerated in hypertensives with controlled resting BP

Literature - June 20, 2018 - Chant B, et al. - Hypertension 2018

BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.

Longer exposure to hypertension in mid-life increases risk of dementia

Literature - June 19, 2018 - Abell JG et al. - Eur Heart J 2018
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension

Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension

Importance of hypertension in CVD prevention

Clinical updates in management of cardiovascular risk (3/4)

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

First messages from the 2018 ESC/ESH Guidelines for treatment of hypertension

News - June 14, 2018

Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.

Obesity associated with high CV risk even in the absence of metabolic abnormalities

Literature - June 13, 2018 - Eckel N, et al. - Lancet Diab Endocrin 2018
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

Renal denervation in the presence of antihypertensive drugs results in BP reduction

Literature - June 6, 2018 - Kandzari DE, et al. - The Lancet 2018

Hypertensive patients treated with renal denervation in the presence of antihypertensive drugs had reduced BP levels compared to sham controls in the SPYRAL HTN-ON MED trial.

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany
After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.